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SUMMARY – Toxicity of chemotherapy is a factor that most negatively aff ects the quality of life 
of cancer patients. Monitoring of side eff ects and adverse eff ects may be subject to errors due to vari-
ous factors such as the lack of privacy during data collection, shame on the part of the patient to talk 
about some issues, lack of recognition of symptoms and/or unawareness of side eff ects of treatments, 
and/or inappropriate reference model of data collection. In order to assist caregivers in proper data 
collection, a ‘self-reporting questionnaire’ was designed. Th e questionnaire was developed using vali-
dated scales such as the Common Terminology Criteria for Adverse Event, Edmonton Symptom 
Assessment Scale and Douleur Neuropathique en 4 Questions. Th e survey involved the population of 
patients scheduled for chemotherapy in Day Hospital at the Campus Bio-Medico University Hospi-
tal, Rome, between June and July 2015. During the period of observation, 367 patients were admitted 
to Day Hospital, 57.5% of women and 38.4% of men, average age 64 years, for a total of 622 accesses; 
of these, only 173 were interviewed by the nursing staff  in relation to side eff ects and toxicity. During 
the trial, 381 patients were involved, of which 60.1% of women (p=0.8) and 38.3% of men (p=0.9), 
average age 63 years (p=0.9), for a total of 611 accesses and 498 self-reporting questionnaires admin-
istered. At the end of the trial period, in order to evaluate usability, an evaluation questionnaire was 
given to medical personnel, including fi ve doctors and six nurses, to consider possible amendments to 
the instrument and its perceived eff ectiveness. Comparative analysis of data collected during the ob-
servation period and the trial showed how the use of the self-reporting questionnaire allowed for de-
tection of side eff ects of chemotherapy earlier and in a more detailed way than relying only on medical 
examination and unstructured interview by nursing staff . It also enabled reaching a larger number of 
users. In conclusion, the use of self-reporting systems, together with the work and clinical judgment 
of the expert, can contribute to improvement in the patient quality of life, corroborating nurse inter-
views through a precise and systematic data collection process that reduces the amount of interpreta-
tion of symptoms by the patient and the caregiver, while providing them with precise instructions on 
what to report and how to report it. Th e signifi cant and rapid spread of computers, tablets and smart-
phones allows for speculating on further use and implementation of this system through its computer-
ized application.
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Introduction
Toxicity of chemotherapy is a factor that most neg-
atively aff ects the quality of life of cancer patients. Cy-
totoxic eff ects1-3 become evident as undesirable clinical 
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symptoms that occur after administration of most an-
ti-cancer therapies, due to the low therapeutic index of 
chemotherapy drugs4-6. Th e problem associated with 
this therapy is poor cellular selectivity; moreover, toxic 
eff ects often overlap with therapeutic eff ects as healthy 
cells are also damaged by the treatment. Th ese symp-
toms usually disappear once the treatment ends, but 
their underestimation, lack of timely treatment, or per-
petration of exposure to chemotherapeutic agents may 
lead to irreversible damage to the patient or to the 
need to suspend a therapeutically eff ective treatment, 
thus causing death.
In managing side eff ects, it is essential to know the 
probability of toxic response1,3,7 to chemotherapy and 
to properly assess the signs and symptoms in the pa-
tient before and during treatment, to avoid errors in 
therapeutic decisions. Cancer patients may indeed 
show one or more symptoms related to the disease 
and/or to therapies that infl uence their daily life, inde-
pendently of the stage and spread of the disease; often 
in addition, some symptoms are not immediately rec-
ognized or are underestimated by the oncologist8.
Monitoring of side eff ects and adverse events may, 
however, also be subject to errors and/or omissions due 
to various factors including the lack of privacy during 
data collection, shame on the side of the patient to talk 
about some issues, the lack of recognition of symp-
tomatology and/or unawareness of the treatment side 
eff ects, or inappropriate reference model of data col-
lection9,10.
To this purpose, validated scales11 have been estab-
lished to provide support in detection and treatment of 
symptoms, with the aim to improve the quality of life 
of patients and their families and guarantee continu-
ous care through early integration of simultaneous care 
fi rst and palliative care afterwards.
In the literature, there are no articles on validation 
of a ‘self-reporting questionnaire’ in terms of detection 
of toxicity and side eff ects associated with chemother-
apy. However, fi eld studies use this technique for col-
lecting monitoring data in home care and outpatient 
environments through the application of the Common 
Terminology Criteria for Adverse Event (CT-
CAE)12,13. Studies suggest CTCAE as a valid source of 
information in addition to clinical data for detection 
of chemotherapy toxicity14,15.
In this regard, this project aimed to create a self-
reporting questionnaire in order to improve data col-
lection related to chemotherapy side eff ects, improve 
reception of the patient, and minimize prescription 
errors due to:
• absence of dedicated reception areas;
• lack of privacy;
• uneasiness;
• non-recognition of symptoms;
• patient inability to describe or quantify symp-
toms;
• unawareness of side eff ects of treatments; and
• inadequate reference model of data collection.
Subjects and Methods
In order to assess usefulness and eff ectiveness of 
the self-reporting questionnaire administered to can-
cer patients, a one-month period of observation was 
carried out on the data collection method utilized by 
the medical and nursing staff  at the Oncology Day 
Hospital, Campus Bio-Medico di Roma. It was fol-
lowed by a comparable period of experimentation of 
the self-reporting questionnaire.
Th e self-reporting questionnaire (available on re-
quest) has been developed using validated scales such 
as the CTCAE12,13, the Edmonton Symptom Assess-
ment Scale (ESAS)16,17, and Douleur Neuropathique 
en 4 Questions (DN4)18,19.
In developing the questionnaire, symptoms were 
considered that are more easily recognizable and quan-
tifi able by the patient, and the manifestation of which 
precludes administration of chemotherapy.
At the end of the trial period, an evaluation ques-
tionnaire was given to physicians and nurses in the 
Oncology Day Hospital to assess the usability of the 
self-reporting questionnaire.
Th e evaluation questionnaire on practicality and 
usability of the self-reporting questionnaire by health 
workers has been designed on the basis of previous in-
ternal reports performed at the Hospital Campus Bio-
Medico of Rome by the Group of Improvement JCI 
( Joint Commission International) Clinical Risk Man-
agement, as well as the usability requirements ex-
pressed in the Development of a Model of Integrated 
Patient Folder project of the Ministry of Health20.
Eight questions were identifi ed with 5 possible an-
swers on a Likert scale, from excellent to inadequate, 
in addition to the years of service in the oncology area, 
particularly at the Day Hospital, and 3 open questions.
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Sample
Th e self-reporting questionnaire was administered 
to all patients scheduled for chemotherapy in Day 
Hospital at the Campus Bio-Medico of Rome, with 
approval from the Hospital Health Management. A 
total of 498 questionnaires were administered.
During the period of observation, 367 patients 
were admitted to Day Hospital, 57.5% of women and 
38.4% of men, average age 64 years. For 4.1% of them, 
it was not possible to determine their sexual category 
because of incomplete master data. Total number of 
accesses was 622; of these, 173 were interviewed by the 
nursing staff  concerning side eff ects and toxicity.
During the trial, 381 patients were involved, 60.1% 
of women (p=0.8) and 38.3% of men (p=0.9), average 
age 63 years (p=0.9), while for 1.6% it was not possible 
to determine sexual category. Total number of admis-
sions was 611.
Th e following therapies were administered during 
the two study periods: alkylating agents 2.2% vs. 3.5%, 
p=0.8, 13% vs. 10.4% antimetabolites p=0.7, antimi-
totic 9.4% vs. 10.7%, p=0.94, cytotoxic antibiotics 
0.5% vs. 0% p=0.47, targeted therapies 30.4% vs. 33.3% 
p=0.77, hormones and hormone antagonists 6.9% vs. 
5.6% p=0.93, various agents 4.7% vs. 4.2% p=0.86, and 
polychemotherapies 32.9% vs. 32.3% p=0.95.
Th e two samples did not show statistically signifi -
cant diff erences and were found to be consistent with 
the existing clinical and epidemiological national 
studies4.
Th e medical staff  of the Department of Oncology 
Day Hospital, Campus Bio-Medico University Hos-
pital, Rome, which fi lled-out the evaluation question-
naire consisted of 5 medical specialists, including 2 
specialists and 3 interns; as for the nursing staff , the 
questionnaire was administered to 6 nurses working in 
the oncology area in June, totaling 11 questionnaires to 
assess the usability of the tool.
Th e two populations were compared by standard 
statistical measurements of the mean, standard devia-
tion and percentage. Th e values of p were calculated by 
the χ2-test for discontinuous variables and Student’s T 
test for continuous variables. Th e values of p<0.05 were 
considered statistically signifi cant.
Th e study was approved by the Ethics Committee 
of the Campus Bio-Medico University Hospital, 
Rome, Italy.
Results
Th e research results proved to be consistent with 
those reported from scientifi c studies in the fi eld. 
Comparative analysis of data collected during the ob-
servation period and the trial revealed that the use of 


















Fig. 1. Toxicity revelation.
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the self-reporting questionnaire allowed for detection 
of chemotherapy side eff ects earlier and in a more de-
tailed way than relying only on medical examination 
and unstructured interviewing by nursing staff . It also 
enabled reaching a larger number of users (Table 1, 
Fig. 1).
Careful analysis of the types of toxicity observed in 
the nursing interviews and questionnaires showed how 
the adverse event monitoring by clinicians during che-
motherapy often did not take into account the subjec-
tive and emotional components, as well as the implica-
tion these symptoms may have in daily life; compari-
son of the symptoms self-reported by patients with 
those recorded by nurses revealed that patients and 
nurses agreed on the incidence of the most common 
and/or objectifi able symptoms such as hyperthermia 
and gastric toxicity, but they did not agree on less 
widespread toxicities that go unrecognized by the pop-
ulation as potential eff ects of chemotherapy, as well as 
on psychosomatic states. Th ese conditions often are 
not considered really compromising by attending phy-
sicians from a prescriptive point of view, but prove to 
be highly invalidating21-23 from the point of view of 
patients. In particular, highly signifi cant results are 
achieved concerning the presence of alteration of bow-
el function, pain, anxiety and depression, malaise, fa-
tigue and abnormal sleep-rest pattern8,24, as such tox-
icities, very frequently suggested by patients, tend to be 
underestimated and undervalued by operators25-29 
(Table 2, Fig. 2).
Discussion and Conclusions
Th e use of self-reporting systems, together with the 
work and clinical judgment of the expert, can contrib-
ute to improvement in the quality of life of cancer pa-
tients. It also helps the nurse in conducting patient 
interview through precise and systematic data collec-
Table 2. Chemotherapy toxicity and side eff ects
Toxicity and side eff ects Observational group (%) Experimental group (%) p
Common 
Terminology 
Criteria for Adverse 
Event (CTCAE)
Hyperthermia 2.3 3.6 0.9
Skin reaction  2.3 18.7 0.0004
Mucositis 0 16.5 0.0001
Gastric toxicity 1.2 6 0.14





Pain 4 41.4 0.0000
Tiredness 5.8 74.1 0.0000
Nausea 2.3 28.9 0.0000
Depression 0 31.7 0.0000
Anxiety 0 41.6 0.0000
Drowsiness 0 51.4 0.0000
Lack of appetite 0 33.1 0.0000
Wellbeing 0.6 40.2 0.0000
Shortness of breath 0 24.9 0.0000
Douleur 
neuropathique 
en 4 questions 
(DN4)
Burn 0 9.8 0.0039
Cold 0 6.2 0.0339
Electric shock 0.6 11.4 0.0035
Numbness 2.9 25.9 0.0000
Painful cold 0 5.6 0.0486
Electric shock 0 10 0.0035
Itching 0.6 11.6 0.0031
Pain evoked by light touching 0 8.6 0.0181
Others 5.8 23.1 0.0010
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Fig. 2. Chemotherapy toxicity and side eff ects.
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tion. Th is in turn reduces the interpretative amount of 
symptoms by patients and caregivers, while providing 
them with precise instructions on what to report and 
how to report it.
Th e method of self-administration also guarantees 
more privacy and freedom to reveal symptoms that are 
deemed embarrassing. Th e use of a standardized form 
allows for reporting real and relevant data into com-
puterized medical records, thus guaranteeing storage 
of information towards greater continuity of care.
Th e tool also shows good versatility of use; its use 
as a checklist during the active interview by physicians 
and nurses can be anticipated, in addition to the self-
administration mode, whereas privacy conditions are 
guaranteed.
Th e signifi cant and rapid availability of computers, 
tablets and smartphones, which in recent years has in-
volved not only young people but also people of all 
ages and social classes, also allows to envision further 
use and implementation of this system through its 
computerized application, as already happens interna-
tionally30. Specifi cally, one might think to fi ll-in an 
online questionnaire in order to allow regular moni-
toring of patient symptoms, their performance status 
and their needs, as well as to obtain information on the 
patient health in real-time, thus improving effi  ciency 
and quality of care, communication and help requests31.
Th e use of telemedicine systems in oncology is ex-
pected to be on an equal footing with those already 
widespread in Italy for the care of patients with chron-
ic degenerative diseases. Th e use of such technologies 
would improve clinical care32 by reporting symptoms 
with consistent time savings through standardized 
methods and addressing useful links for clinical treat-
ment, such as summary reports in the patient comput-
erized medical record and immediate e-mail alerts to 
healthcare personnel whenever patients report acute 
needs33.
Ultimately, the importance of maintaining an ef-
fective physician/nurse-patient relationship cannot be 
underemphasized in order to avoid depersonalization 
of the helping relationship that the exclusive use of 
computerized methods may entail.
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Sažetak
USPOREDBENO ISTRAŽIVANJE METODA PRIKUPLJANJA PODATAKA 
U PROCESU SESTRINSKE NJEGE: OTKRIVANJE NUSPOJAVA KEMOTERAPIJE 
POMOĆU UPITNIKA ZA SAMOPROCJENU
M. Di Muzio, A. Marinucci, A. De Benedictis i D. Tartaglini
Toksičnost kemoterapije je čimbenik koji ima najteži učinak na kvalitetu života u bolesnka s karcinomom. Praćenje nus-
pojava i štetnih učinaka može biti podložno greškama zbog raznih čimbenika kao što je nedostatna zaštita povjerljivosti 
 tijekom prikupljanja podataka, nevoljkosti bolesnika da govori o nekim problemima, neprepoznavanje simptoma i/ili 
 nepoznavanje nuspojava liječenja i/ili neodgovarajući referentni model prikupljanja podataka. Zato smo izradili upitnik za 
samoprocjenu kako bismo pomogli u ispravnom prikupljanju podataka onima koji pružaju skrb ovim bolesnicima. Upitnik je 
izrađen uz pomoć provjerenih ljestvica kao što su Common Terminology Criteria for Adverse Event, Edmonton Symptom 
 Assessment Scale i Douleur Neuropathique en 4 Questions. Istraživanje je obuhvatilo bolesnike naručene za kemoterapiju u 
Dnevnoj bolnici Sveučilišne bolnice Campus Bio-Medico u Rimu u lipnju i srpnju 2015. godine. U tom razdoblju u Dnevnu 
bolnicu je primljeno 367 bolesnika, 57,5% žena i 38,4% muškaraca prosječne dobi od 64 godine, za ukupno 622 pristupa. Od 
svih tih bolesnika sestrinsko osoblje je samo njih 173 ispitalo o nuspojavama i toksičnosti. Za vrijeme istraživanja bio je 
uključen 381 bolesnik, od toga 60,1% žena (p=0,8) i 38,3% muškaraca (p=0,9) prosječne dobi od 63 godine (p=0,9), za 
 ukupno 611 pristupa i 498 izdanih upitnika za samoprocjenu. Kako bismo procijenili primjenjivost ovoga upitnika, na kraju 
istraživanja upitnik za njegovu procjenu je podijeljen medicinskom osoblju uključujući pet liječnika i šest medicinskih sesta-
ra kako bi razmotrili moguće potrebne dopune ovoga instrumenta te njegovu učinkovitost. Usporedbena analiza podataka 
prikupljenih tijekom istraživanja pokazala je da je primjena upitnika za samoprocjenu omogućila otkrivanje nuspojava kemo-
terapije ranije i podrobnije nego kad se to oslanjalo samo na medicinski pregled i nestrukturirani razgovor sestrinskog osoblja 
s bolesnicima. Uz to, ovom metodom je obuhvaćen veći broj korisnika. U zaključku, primjena sustava za samoprocjenu zajed-
no sa stručnim radom i kliničkom prosudbom može doprinijeti poboljšanju bolesnikove kvalitete života, pružiti potporu 
razgovoru sestrinskog osoblja s bolesnikom kroz proces preciznog i sustavnog prikupljanja podataka, čime se znatno smanju-
je tumačenje simptoma od strane bolesnika i osoba koje ih njeguju, ali im pruža točne upute o čemu trebaju izvijestiti i kako. 
Zahvaljujući značajnom i brzom širenju računala, tableta i ‘pametnih telefona’ može se promišljati o daljnjoj primjeni ovoga 
sustava kroz njegovu računalnu aplikaciju.
Ključne riječi: Sestrinska njega, postupci; Podaci, prikupljanje; Tumori – farmakoterapija; Antitumorski lijekovi – štetna djelo-
vanja; Ankete i upitnici; Samoprocjena
